Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02655978
Other study ID # 02-15-35
Secondary ID KL2TR000440
Status Completed
Phase
First received
Last updated
Start date January 2016
Est. completion date October 2019

Study information

Verified date November 2020
Source University Hospitals Cleveland Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The overall goal of this study is to employ diffusion-weighted imaging (DWI) and tractography to investigate differences in connectivity in the rostral dorsal cingulum bundle (CB) in patients with bipolar disorder type I (BDI) or bipolar type II (BDII) compared to matched controls, and to utilize this information to determine if high-frequency deep brain stimulation (DBS) of the rostral dorsal CB has realistic potential as a therapy for producing mood stabilization in patients with BDI or BDII.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date October 2019
Est. primary completion date October 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility 1. Inclusion and Exclusion Criteria for Group 1: Healthy Volunteers a. Inclusion Criteria for Group 1: i. Male or female, age 18 or older ii. In the opinion of the investigator, capable of understanding and complying with protocol requirements iii. In the opinion of the investigator, has the competency to understand and sign the informed consent iv. Physically healthy v. Without any current and/or lifetime psychiatric disorder assessed with a Structured Clinical Interview for psychiatric Disorders, including the Mini International Neuropsychiatric Interview (MINI) b. Exclusion Criteria for Group 1: i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis) ii. Progressive neurological disease such as neurodegenerative disease iii. Preexisting implanted electrical device (such as pacemaker or cardiac defibrillator) iv. Any psychiatric disorder including any severe personality disorder v. Currently pregnant or planning to become pregnant vi. Any other contraindications to the brain imaging procedures. vii. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription viii. Currently taking any steroids, stimulants, or opioid pain killers. ix. Currently experiencing nicotine dependence or any smoking of cigarettes or use of other nicotine containing products within a week before the imaging visit. 2. Inclusion and Exclusion Criteria for Group 2: Medically Treatment-Responsive Bipolar Disorder a. Inclusion Criteria for Group 2: i. Male or female, age 18 or older ii. In the opinion of the investigator, capable of understanding and complying with protocol requirements iii. In the opinion of the investigator, has the competency to understand and sign the informed consent iv. Meets diagnostic criteria for BDI or BDII according to the DSM-V criteria, as confirmed by a systematic clinical interview and the administration of the MINI v. A recent episode of depression, currently in remission with evidence-based treatments for bipolar disorder vi. Montgomery-Asberg Depression Rating Scale (MADRS) total score = 10 vii. Young Mania Rating Scale (YMRS, Young et al 1988) total score = 8 viii. Global Clinical Impression-Severity for Bipolar Disorder (CGI-S-BD) = 2 ix. Subject is compliant with taking medication per the investigator's discretion b. Exclusion Criteria for Group 2: i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis) ii. Progressive neurological disease such as neurodegenerative disease iii. Preexisting implanted electrical device (such as pacemaker or cardiac defibrillator) iv. Contribution of any co-occurring psychiatric comorbidity that is disproportionate to the contribution of BDI or BDII, such as severe obsessive-compulsive disorder (OCD) or post-traumatic stress disorder (PTSD) v. Meets criteria for antisocial personality disorder vi. Meets criteria for having borderline personality disorder vii. There will be no exclusions based on prescribed CNS-active medications viii. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription ix. Meets DSM-V criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine and/or nicotine x. Currently pregnant or planning to become pregnant xi. Any other contraindications to the brain imaging procedures. 3. Inclusion and Exclusion Criteria for Group 3: Treatment-Refractory Bipolar Disorder a. Inclusion Criteria for Group 3: i. Male or female, age 18 or older ii. In the opinion of the investigator, capable of understanding and complying with protocol requirements iii. In the opinion of the investigator, has the competency to understand and sign the informed consent iv. Meets diagnostic criteria for BDI or BDII, currently depressed, at least moderately severe with or without psychotic features, according to the DSM-V criteria, as confirmed by a systematic clinical interview and the administration of the Structured Clinical Interview for Psychiatric Disorders, including the Mini International Neuropsychiatric Interview (MINI) v. Current episode lasting at least 6 months and not responding to 2 adequate evidence-based treatments for BDI or BDII assessed with the assistance of Modified Antidepressant Treatment History Form (MATHF) and verified through medical records if possible vi. If a subject has refused treatment with a particular FDA-approved mood stabilizer due to reasons of unacceptable side effects (such as weight gain, etc.), their wishes will be respected vii. Depression severity should be measured with Montgomery-Asberg Depression Rating Scale (MADRS). A MADRS total score = 20 is required at Screening Visit/Baseline Evaluation. viii. Has experienced marked impairment as documented by a score consistent with severe impairment (7 or more on at least one of the three subscales of the Sheehan Disability Scale (SDS), which includes an assessment of work-life, family-life, and social life (no/mild impairment 0-3, moderate impairment 4-6, severe impairment 7-10) ix. Bipolar disorder and current depressive episode as the primary source of the patient's disability, according to both the subject and the psychiatrist b. Exclusion Criteria for Group 3: i. Significant structural brain lesion identified (e.g. infarct, hemorrhage, tumor, multiple sclerosis) ii. Progressive neurological disease such as neurodegenerative disease iii. Preexisting implanted electrical device (such as pacemaker or cardiac defibrillator) iv. Contribution of any co-occurring psychiatric comorbidity that disproportionate to the contribution of BDI or BDII, such as severe obsessive-compulsive disorder (OCD) or post-traumatic stress disorder (PTSD) v. Meets criteria for antisocial personality disorder vi. Meets criteria for having borderline personality disorder vii. There will be no exclusions based on prescribed CNS-active medications viii. Tests positive for illegal substances or prescription medications for which they do not have a valid prescription ix. Meets DSM-V criteria for any alcohol and/or drug use disorder within the last 6 months, excluding the use of caffeine and/or nicotine x. Active suicidal ideation with a plan or intent, a suicide attempt within past 6 months or more than 2 suicide attempts within the past 2 years xi. Currently pregnant or planning to become pregnant xii. Any other contraindications to the brain imaging procedures.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Magnetic Resonance Imaging


Locations

Country Name City State
United States University Hospitals Cleveland Medical Center Cleveland Ohio

Sponsors (2)

Lead Sponsor Collaborator
University Hospitals Cleveland Medical Center National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Differences in connectivity in the rostral dorsal CB in patients with BDI or or BDII compared to matched controls The imaging visit will consist of an MRI with diffusion-weighted imaging (DWI) sequences Day 1
See also
  Status Clinical Trial Phase
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT02855762 - Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder N/A
Recruiting NCT05915013 - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response Phase 1
Recruiting NCT05206747 - Ottawa Sunglasses at Night for Mania Study N/A
Completed NCT02513654 - Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects Phase 1
Recruiting NCT06313918 - Exercise Therapy in Mental Disorders-study N/A
Completed NCT02304432 - Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine Early Phase 1
Recruiting NCT06197048 - Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder N/A
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT02212041 - Electronic Cigarettes in Smokers With Mental Illness N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Not yet recruiting NCT04432116 - Time and Virtual Reality in Schizophrenia and Bipolar Disorder N/A
Terminated NCT02909504 - Gao NARASD Lithium Study Phase 4
Terminated NCT02893371 - Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
Completed NCT02970721 - Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
Recruiting NCT03088657 - Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
Recruiting NCT02481245 - BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study Phase 2